Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.

PloS One
Jen C WangStephen Lichter

Abstract

Myelofibrosis (MF), including primary myelofibrosis, post-essential thrombocythemia MF, and post-polycythemia vera MF, has been reported to be associated with autoimmune phenomena. IMiDs have been reported to be effective in some patients with MF, presumably for their immune-modulator effects. We therefore sought to elucidate the immune derangements in patients with MF. We found no differences in T regulatory cells (Treg) and T helper 17 (Th17) cells in MF patients and normal healthy controls. However, we found significantly elevated soluble interleukin 2 alpha (sIL2Rα) in MF patients compared to those with other myeloproliferative neoplasm diseases and normal healthy controls. Our studies with MF patients further revealed that Treg cells were the predominant cells producing sIL2Rα. sIL2Rα and IL2 complex induced the formation of Treg cells but not the formation of Th1 or Th17 cells. sIL2Rα induced CD8+ T cell proliferation in the presence of Treg cells. Monocytes or neutrophils had no effect on the production of sIL2Rα by Treg cells. Furthermore, we found plasma sIL2Rα levels were correlated to the auto-immune serology in MPN patients and ruxolitinib significantly inhibits the sIL2Rα production by the Treg cells in MF patients...Continue Reading

References

Jun 1, 1978·British Journal of Haematology·C M Lewis, G D Pegrum
Sep 1, 1976·The American Journal of the Medical Sciences·B Bernhardt, M Valletta
Aug 1, 1990·American Journal of Hematology·H Hasselbalch
Aug 1, 1969·The American Journal of the Medical Sciences·M KhumbanondaM E Eyster
Feb 1, 1994·British Journal of Haematology·J C Wang, A Wang
Feb 1, 1997·American Journal of Hematology·M L RandiF Fabris
Oct 2, 1998·Advances in Immunology·B H Nelson, D M Willerford
Jan 7, 2003·Journal of Immunotherapy·Luv Ram Javia, Steven A Rosenberg
Dec 10, 2003·The Journal of Experimental Medicine·Craig A MurphyDaniel J Cua
Mar 24, 2004·Seminars in Immunology·Herman WaldmannYuki Tone
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tomás AlvaroMiguel A Piris
Mar 24, 2005·Nature Immunology·Yasmine Belkaid, Barry T Rouse
Sep 10, 2005·Blood·Rao H PrabhalaNikhil C Munshi
Dec 6, 2005·Cancer Immunology, Immunotherapy : CII·Koji KonoHideki Fujii
Apr 13, 2006·Blood·Ayalew TefferiHagop M Kantarjian
Apr 28, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andreas E AlbersAlbert B De Leo
Apr 7, 2007·Blood·Shahram Y KordastiGhulam J Mufti
Oct 2, 2007·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·E Bien, A Balcerska
Jul 29, 2008·Biochemical and Biophysical Research Communications·Bin ZhangGuoen Fang
Oct 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Yoshihiro MiyaharaRong-Fu Wang
Jan 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lisa M MaierDavid A Hafler
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaSrdan Verstovsek
Jan 7, 2010·American Journal of Hematology·Ruben A MesaAyalew Tefferi
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Feb 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ayalew TefferiAnimesh Pardanani

❮ Previous
Next ❯

Citations

Dec 8, 2015·Mediators of Inflammation·Christophe DesterkeMarie-Caroline Le Bousse-Kerdilès
Feb 13, 2018·Journal of Immunology Research·Giovanni D'ArenaDaniela Fenoglio
Oct 3, 2018·Leukemia & Lymphoma·Sonia Emilia SeliceanIoana Berindan-Neagoe
Apr 5, 2020·Expert Opinion on Investigational Drugs·Aniket Bankar, Vikas Gupta
Aug 20, 2016·Annals of Hematology·Lindsey ShantzerJeffrey J Pu

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
flow cytometry
PMA

Software Mentioned

FlowJo
GraphPad Prism

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.